Details of the Drug

General Information of Drug (ID: DM1RBYG)

Drug Name

Nitric Oxide

Synonyms

Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO; HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Methicillin-resistant staphylococci infection	1A00-1A09	Approved	[2]
Pneumonia	CA40	Approved	[2]
Pulmonary hypertension	BB01	Approved	[2]
Respiratory failure	CB41	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Tinea pedis	1F28.2	Discontinued in Phase 2	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Bronchodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

30.006

Logarithm of the Partition Coefficient (xlogp)

0.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 6 seconds [6]
Metabolism: The drug is metabolized via pulmonary capillary bed []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Apoptosis	Not Available	nor3	OTMTFC76	[7]
Apoptosis	Not Available	GOSR1	OTX8TMVU	[7]
-----------

Chemical Identifiers

Formula: NO
IUPAC Name: nitric oxide
Canonical SMILES: [N]=O
InChI: InChI=1S/NO/c1-2
InChIKey: MWUXSHHQAYIFBG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 145068
ChEBI ID: CHEBI:16480
CAS Number: 10102-43-9
DrugBank ID: DB00435
TTD ID: D0A5FM
VARIDT ID: DR01184

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylate cyclase (GC)	TT6HPVC	NOUNIPROTAC	Stimulator	[8]
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN ; GCYB1_HUMAN	Stimulator	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)	DTW7AE3	AAAT_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Regulation of Drug Effects	[11]
Annexin A5 (ANXA5)	OTZS877V	ANXA5_HUMAN	Gene/Protein Processing	[12]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[13]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Protein Interaction/Cellular Processes	[13]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Gene/Protein Processing	[13]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[13]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Gene/Protein Processing	[13]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[13]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Gene/Protein Processing	[14]
Beta-galactosidase (GLB1)	OTB0TKAG	BGAL_HUMAN	Gene/Protein Processing	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nitric Oxide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Nitric Oxide and Prilocaine.	Pain [MG30-MG3Z]	[16]
-----------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207141.
2	Nitric Oxide FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2509).
4	ClinicalTrials.gov (NCT04290858) Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. U.S. National Institutes of Health.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024215)
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
9	Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
10	Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
11	[Peroxisome proliferator-activated receptor activator troglitazone inhibits angiotensin II-stimulated secretion of vasoactive factors by endothelial cells]. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jul;27(7):1030-3.
12	Nitric oxide-induced apoptosis in lymphoblastoid and fibroblast cells dependent on the phosphorylation and activation of p53. Cancer Res. 2005 Jul 15;65(14):6097-104. doi: 10.1158/0008-5472.CAN-04-4254.
13	Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
14	Serum clara-cell protein and beta2-microglobulin as early markers of occupational exposure to nitric oxides. Inhal Toxicol. 2005 Feb;17(2):87-97. doi: 10.1080/08958370590899460.
15	Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):17018-23. doi: 10.1073/pnas.0607873103. Epub 2006 Oct 30.
16	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".